LT2776469T - Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40 - Google Patents

Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40

Info

Publication number: LT2776469T
Authority: LT; Lithuania
Prior art keywords: human; specific; moleculars; antibody; antibody moleculars
Prior art date: 2011-11-11

Application number

LTEP12803508.6T

Other languages

English (en)

Lithuanian (lt)

Inventor

Ralph Adams

Pallavi BHATTA

Sam Philip Heywood

David Paul Humphreys

Original Assignee

Ucb Biopharma Sprl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-11

Filing date

2012-11-09

Publication date

2019-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47388492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2776469(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-09 Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl

2019-08-12 Publication of LT2776469T publication Critical patent/LT2776469T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LTEP12803508.6T 2011-11-11 2012-11-09 Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40 LT2776469T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161558545P	2011-11-11	2011-11-11
PCT/EP2012/072325 WO2013068563A2 (en)	2011-11-11	2012-11-09	Antibody molecules having specificity for human ox40

Publications (1)

Publication Number	Publication Date
LT2776469T true LT2776469T (lt)	2019-08-12

Family

ID=47388492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP12803508.6T LT2776469T (lt)	2011-11-11	2012-11-09	Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40

Country Status (35)

Country	Link
US (2)	US9040048B2 (es)
EP (1)	EP2776469B1 (es)
JP (1)	JP6367714B2 (es)
KR (1)	KR102071054B1 (es)
CN (1)	CN103946240B (es)
AP (1)	AP2014007668A0 (es)
AR (1)	AR088820A1 (es)
AU (1)	AU2012333997B2 (es)
BR (1)	BR112014011404A2 (es)
CA (1)	CA2855174C (es)
CL (1)	CL2014001193A1 (es)
CO (1)	CO7010784A2 (es)
CY (1)	CY1122073T1 (es)
DK (1)	DK2776469T3 (es)
EA (1)	EA035112B1 (es)
EC (1)	ECSP14000329A (es)
ES (1)	ES2737998T3 (es)
HR (1)	HRP20191219T1 (es)
HU (1)	HUE044333T2 (es)
IL (1)	IL232420B (es)
LT (1)	LT2776469T (es)
MA (1)	MA35724B1 (es)
MX (1)	MX358391B (es)
MY (1)	MY183795A (es)
PE (1)	PE20141995A1 (es)
PH (1)	PH12014500946A1 (es)
PL (1)	PL2776469T3 (es)
PT (1)	PT2776469T (es)
SG (1)	SG11201402093RA (es)
SI (1)	SI2776469T1 (es)
TN (1)	TN2014000206A1 (es)
TR (1)	TR201910721T4 (es)
TW (1)	TWI588155B (es)
UA (1)	UA112203C2 (es)
WO (1)	WO2013068563A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG2014014708A (en) *	2009-02-17	2014-05-29	Ucb Pharma Sa	Antibody molecules having specificity for human ox40
WO2011030107A1 (en) *	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
AP2013006771A0 (en)	2010-08-23	2013-03-31	Boards Of Regents The University Of Texas System	Anti-OX40 antibodies and methods of using the same
GB201116092D0 (en)	2011-09-16	2011-11-02	Bioceros B V	Antibodies and uses thereof
PH12014500456A1 (en) *	2011-09-16	2014-04-14	Ucb Pharma Sa	Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
DK2976361T3 (en)	2013-03-18	2018-10-01	Biocerox Prod Bv	HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
WO2015041515A1 (en)	2013-09-19	2015-03-26	N.V. Nutricia	Improved process for the humanization of animal skim milk
CA2943834A1 (en)	2014-03-31	2015-10-08	Genentech, Inc.	Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
CN114504652A (zh)	2015-03-03	2022-05-17	科马布有限公司	抗体、用途和方法
US20180044429A1 (en)	2015-03-09	2018-02-15	Celldex Therapeutics, Inc.	Cd27 agonists
GB201506868D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method for protein purification
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
EA201792451A1 (ru) *	2015-05-07	2018-05-31	Агенус Инк.	Антитела к ox40 и способы их применения
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
MX2018003820A (es) *	2015-10-02	2018-12-10	F Hoffmann La Roche Ag	Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
JP6771551B2 (ja) *	2015-10-15	2020-10-21	ディンフーバイオターゲットカンパニーリミテッド	抗ｏｘ４０抗体及びその応用
IL299072A (en) *	2015-12-02	2023-02-01	Memorial Sloan Kettering Cancer Center	Antibodies and methods for using them
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
AU2016364891A1 (en) *	2015-12-03	2018-06-07	Agenus Inc.	Anti-OX40 antibodies and methods of use thereof
BR112018076281A2 (pt)	2016-06-20	2019-03-26	Kymab Limited	imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3041340A1 (en) *	2016-11-09	2018-05-17	Agenus Inc.	Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EP4467565A3 (en)	2016-12-21	2025-03-12	Amgen Inc.	Anti-tnf alpha antibody formulations
CN112638375A (zh)	2018-06-15	2021-04-09	旗舰创业创新五公司	通过后细胞信号传导因子的调节来增加免疫活性
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
AU2020326087A1 (en)	2019-08-02	2021-12-16	UCB Biopharma SRL	Methods for purifying antibodies
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JOP20220151A1 (ar)	2019-12-17	2023-01-30	Amgen Inc	ناهض مستقبل إنترلوكين -2 / tnf المزدوج للاستخدام في العلاج
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US20220325287A1 (en)	2021-03-31	2022-10-13	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
JP2024525475A (ja)	2021-06-29	2024-07-12	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	タノトランスミッションを促進するように操作された免疫細胞及びその使用
EP4598946A1 (en)	2022-10-05	2025-08-13	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2025248017A1 (en)	2024-05-31	2025-12-04	UCB Biopharma SRL	Method of purifying recombinant proteins

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
US5821332A (en)	1993-11-03	1998-10-13	The Board Of Trustees Of The Leland Stanford Junior University	Receptor on the surface of activated CD4+ T-cells: ACT-4
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0124317D0 (en)	2001-10-10	2001-11-28	Celltech R&D Ltd	Biological products
US20040146948A1 (en)	2002-10-18	2004-07-29	Centenary Institute Of Cancer Medicine And Cell Biology	Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
ITRM20030601A1 (it)	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
ITRM20050290A1 (it)	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
TWI461436B (zh)	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US7850965B2 (en)	2005-12-05	2010-12-14	Symphogen A/S	Anti-orthopoxvirus recombinant polyclonal antibody
WO2007112054A2 (en)	2006-03-23	2007-10-04	Sea Lane Biotechnologies, Llc	Facilitation of translocation of molecules through the gastrointestinal tract
AU2008219666A1 (en)	2007-02-27	2008-09-04	Genentech, Inc.	Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
EP2535350B1 (en)	2007-09-26	2018-01-24	UCB Biopharma SPRL	Dual specificity antibody fusions
HRP20170374T1 (hr) *	2008-09-26	2017-05-05	Ucb Biopharma Sprl	Biološki proizvodi
SG2014014708A (en) *	2009-02-17	2014-05-29	Ucb Pharma Sa	Antibody molecules having specificity for human ox40
WO2011030107A1 (en)	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
JP5522668B2 (ja)	2010-02-03	2014-06-18	株式会社ブリヂストン	タイヤ構成部材の切断装置及び製造方法
PL2776466T3 (pl) *	2011-11-11	2018-01-31	Ucb Biopharma Sprl	Przeciwciała wiążące albuminę i ich fragmenty wiążące

2012
- 2012-09-11 UA UAA201404941A patent/UA112203C2/uk unknown
- 2012-11-08 US US13/672,077 patent/US9040048B2/en not_active Expired - Fee Related
- 2012-11-09 CA CA2855174A patent/CA2855174C/en not_active Expired - Fee Related
- 2012-11-09 SG SG11201402093RA patent/SG11201402093RA/en unknown
- 2012-11-09 PE PE2014000673A patent/PE20141995A1/es active IP Right Grant
- 2012-11-09 MY MYPI2014701189A patent/MY183795A/en unknown
- 2012-11-09 HU HUE12803508 patent/HUE044333T2/hu unknown
- 2012-11-09 DK DK12803508.6T patent/DK2776469T3/da active
- 2012-11-09 TW TW101141760A patent/TWI588155B/zh not_active IP Right Cessation
- 2012-11-09 WO PCT/EP2012/072325 patent/WO2013068563A2/en not_active Ceased
- 2012-11-09 KR KR1020147015520A patent/KR102071054B1/ko not_active Expired - Fee Related
- 2012-11-09 MX MX2014005564A patent/MX358391B/es active IP Right Grant
- 2012-11-09 EA EA201400565A patent/EA035112B1/ru not_active IP Right Cessation
- 2012-11-09 SI SI201231633T patent/SI2776469T1/sl unknown
- 2012-11-09 TR TR2019/10721T patent/TR201910721T4/tr unknown
- 2012-11-09 PH PH1/2014/500946A patent/PH12014500946A1/en unknown
- 2012-11-09 AR ARP120104230A patent/AR088820A1/es unknown
- 2012-11-09 PL PL12803508T patent/PL2776469T3/pl unknown
- 2012-11-09 HR HRP20191219TT patent/HRP20191219T1/hr unknown
- 2012-11-09 AU AU2012333997A patent/AU2012333997B2/en not_active Ceased
- 2012-11-09 LT LTEP12803508.6T patent/LT2776469T/lt unknown
- 2012-11-09 CN CN201280055398.8A patent/CN103946240B/zh not_active Expired - Fee Related
- 2012-11-09 AP AP2014007668A patent/AP2014007668A0/xx unknown
- 2012-11-09 BR BR112014011404A patent/BR112014011404A2/pt not_active Application Discontinuation
- 2012-11-09 EP EP12803508.6A patent/EP2776469B1/en active Active
- 2012-11-09 JP JP2014540489A patent/JP6367714B2/ja not_active Expired - Fee Related
- 2012-11-09 PT PT12803508T patent/PT2776469T/pt unknown
- 2012-11-09 ES ES12803508T patent/ES2737998T3/es active Active
2014
- 2014-05-01 IL IL232420A patent/IL232420B/en active IP Right Grant
- 2014-05-07 CL CL2014001193A patent/CL2014001193A1/es unknown
- 2014-05-08 TN TNP2014000206A patent/TN2014000206A1/en unknown
- 2014-05-08 EC ECIEPI2014329A patent/ECSP14000329A/es unknown
- 2014-05-08 CO CO14099147A patent/CO7010784A2/es unknown
- 2014-06-05 MA MA37104A patent/MA35724B1/fr unknown
2015
- 2015-04-27 US US14/697,142 patent/US9873735B2/en active Active
2019
- 2019-07-23 CY CY20191100781T patent/CY1122073T1/el unknown

Also Published As

Publication number	Publication date
KR102071054B1 (ko)	2020-01-29
HUE044333T2 (hu)	2019-10-28
HRP20191219T1 (hr)	2019-10-04
AR088820A1 (es)	2014-07-10
EA201400565A1 (ru)	2014-12-30
CL2014001193A1 (es)	2014-12-26
NZ624583A (en)	2015-05-29
TR201910721T4 (tr)	2019-08-21
PL2776469T3 (pl)	2019-10-31
IL232420A0 (en)	2014-06-30
PH12014500946A1 (en)	2014-06-09
TW201326205A (zh)	2013-07-01
ES2737998T3 (es)	2020-01-17
ECSP14000329A (es)	2016-01-29
PE20141995A1 (es)	2014-12-06
PT2776469T (pt)	2019-07-25
US20160031974A1 (en)	2016-02-04
EP2776469B1 (en)	2019-04-24
US9040048B2 (en)	2015-05-26
SI2776469T1 (sl)	2019-09-30
AP2014007668A0 (en)	2014-05-31
JP6367714B2 (ja)	2018-08-01
CO7010784A2 (es)	2014-07-31
CY1122073T1 (el)	2020-11-25
MX2014005564A (es)	2014-11-10
CA2855174A1 (en)	2013-05-16
EA035112B1 (ru)	2020-04-28
MX358391B (es)	2018-08-17
WO2013068563A3 (en)	2013-06-27
US9873735B2 (en)	2018-01-23
UA112203C2 (uk)	2016-08-10
TWI588155B (zh)	2017-06-21
EP2776469A2 (en)	2014-09-17
AU2012333997B2 (en)	2017-08-31
SG11201402093RA (en)	2014-06-27
JP2015506910A (ja)	2015-03-05
CA2855174C (en)	2021-11-02
IL232420B (en)	2019-02-28
WO2013068563A2 (en)	2013-05-16
KR20140097329A (ko)	2014-08-06
WO2013068563A9 (en)	2014-06-19
DK2776469T3 (da)	2019-07-29
US20130243772A1 (en)	2013-09-19
TN2014000206A1 (en)	2015-09-30
CN103946240A (zh)	2014-07-23
BR112014011404A2 (pt)	2017-05-30
MY183795A (en)	2021-03-16
AU2012333997A1 (en)	2014-05-29
CN103946240B (zh)	2018-02-23
MA35724B1 (fr)	2014-12-01

Publication	Publication Date	Title
LT2776469T (lt)	2019-08-12	Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
SMT202000512T1 (it)	2021-01-05	Anticorpi anti-tau umani
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
PL2731677T3 (pl)	2018-08-31	Przeciwciała wiążące się z OX40 i ich zastosowania
HUE036663T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
BR112013023241A8 (pt)	2018-01-02	melhorias para entidades biológicas imobilizadas
EP2692380A4 (en)	2014-10-29	SYRINGE
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
HRP20181874T1 (hr)	2019-01-11	Anti-cxcr3 protutijela
HRP20181457T1 (hr)	2018-11-16	Anti-htra1 protutijela i postupci uporabe
BR302012002584S1 (pt)	2014-10-14	Configuracao aplicada em inalador
PL2928905T3 (pl)	2019-05-31	Sposób oczyszczania białek terapeutycznych
DK3202789T3 (da)	2020-05-18	Anti-vla-4-antistoffer
PT2931313T (pt)	2019-07-10	Formulações de solução de anticorpos anti-il-23p19 modificados
BR112014008691A2 (pt)	2017-06-13	anticorpos para cd1d
DK3431504T3 (da)	2021-06-28	Antiphospholipase d4-antistof
DK2931748T3 (da)	2017-01-02	Bmp-6-antistoffer
CO6880064A2 (es)	2014-02-28	Métodos terapéuticos
CO6841994A2 (es)	2014-01-20	Anticuerpos
PL395785A1 (pl)	2012-09-10	Zastosowanie medyczne N-etylo-3-amino-4-fenylo-5-okso-2,5-dihydro-1H-pirazolo-1-karbotioamidu
FI20110236A0 (fi)	2011-07-13	Laite mm. jalkahoitojen helpottamiseksi
DK2701783T3 (da)	2021-06-14	Forbindelse til medicinsk anordning
UA22886S (uk)	2012-03-26	Пробка